Transarterial chemoembolization combined with Huaier granule for the treatment of primary hepatic carcinoma

Zhao, Guang Sheng; Liu, Ying; Zhang, Qing; Li, Chuang; Zhang, Yue Wei; Ren, Zhi Zhong; Zhou, Jun; Zhang, Ming

doi:10.1097/md.0000000000007589

Cited by 32 publications

(27 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study suggested that the inconsistent survival effects of previous malignancies should be considered in clinical trial design and recruitment. In most cancer trials, patients with prior cancer diagnosed within a past 5-year interval are excluded from enrolment [15,45,46]. The reasons for the exclusion include the effects on outcomes, unclear adverse effects, tolerance or reduced efficiency of experimental treatments [30].…”

Section: Discussionmentioning

confidence: 99%

The effects of a prior malignancy on the survival of patients with ovarian cancer: a population-based study

Bian¹,

Xia²,

Wang³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background: With the improvement in the prognostic outcomes of multiple malignancies, the population of cancer survivors is growing rapidly and is at higher risk of developing secondary ovarian cancer. However, the prevalence and clinical outcomes of prior cancer among newly diagnosed ovarian cancer patients remain unknown. Methods: Patients diagnosed with ovarian cancer between 2004 and 2015 were identified using the Surveillance, Epidemiology, and End Results database. Patients were divided into two groups based on whether there was a prior malignancy. A multivariate Cox regression analysis was used to calculate all-cause and ovarian-specific survival. Furthermore, we conducted subgroup survival analyses of patients stratified by previous cancer site to explore the associations between prior cancer site and survival outcomes. Results: A total of 52,182 patients with primary ovarian cancer were identified, and 3.6% (n=1,860) had a documented prior malignancy. In multivariate analyses, patients with prior malignancies had a worse all-cause and ovarian cancer-specific prognosis than those without. In subset analyses, patients with a history of thyroid cancer had a better all-cause and ovarian cancer-specific prognosis, and patients with prior colorectal, urinary system, skin, lung, haematologic and stomach cancers were at risk of decreased survival compared to that of patients without a prior cancer. Conclusions: Prior malignancy has an adverse impact on the survival of patients with ovarian cancer, and the impact on prognostic outcomes varies by different prior cancer sites. The inconsistent survival effects of previous malignancies should be considered in clinical trial design and recruitment.

show abstract

Section: Discussionmentioning

confidence: 99%

The effects of a prior malignancy on the survival of patients with ovarian cancer: a population-based study

Bian¹,

Xia²,

Wang³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

show abstract

“…In China, the herb medicine has been widely used in the treatment of HCC [ 3 – 5 ]. In our institute, we have a continuous interest in the treatment of HCC with Chinese herbs [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

The Chinese Medicine, Jiedu Recipe, Inhibits the Epithelial Mesenchymal Transition of Hepatocellular Carcinoma via the Regulation of Smad2/3 Dependent and Independent Pathways

Liang

Zou

Gao

et al. 2018

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. In China, traditional Chinese herb medicine has been widely used in the treatment of HCC. Jiedu Recipe (JR) is a common used prescription which has shown good results against HCC. However, the exact mechanisms of JR are still unknown. Therefore, we investigated the efficacy of JR on HCC in the current study. JR inhibited the cell viability of both SMMC-7721 and Huh7 cells in both time- and dose-dependent manners. Transwell assay revealed that JR decreased the number of migrated cells of SMMC-7721 cells. JR treatment increased the E-cadherin expression level and decreased the levels of p-Smad2/3 and Smad2/3. Further study showed that JR reversed the effect of TGFβ1 on the expression of E-cadherin, vimentin, N-cadherin, and MMP2/9. JR also significantly inhibited TGFβ1-induced migration and invasion of SMMC-7721 and Huh7 cells determined by wound healing assay and transwell assay. TGFβ1 treatment increased the phosphorylation of Smad2/3, p38 MAPK, JNK, ERK1/2, and Akt in SMMC-7721 cells and pretreatment with JR blocked TGFβ1-induced activation of Smad2/3 and Akt and MAPKs. In conclusion, JR inhibits liver cancer cells migration and invasion through epithelial mesenchymal transition (EMT) inhibition via Smad2/3 dependent and independent pathways, suggesting it is an effective therapeutic strategy against HCC metastasis.

show abstract

“…Huaier granules are a new anti-tumor drug extracted from Trametes robiniophila Murr (Huaier) (Zhao et al, 2017 ). Its main active ingredient is a proteoglycan composed of 41.53% polyose, 12.93% amino acid, and 8.72% H 2 O (Zou et al, 2015 ).…”

Section: Chinese Medicine Preparations For Dsmmentioning

confidence: 99%

Recent Advances in Herbal Medicines for Digestive System Malignancies

et al. 2018

View full text Add to dashboard Cite

Herbal medicines, as an important part of traditional Chinese medicine (TCM), have been used to treat digestive system malignancies (DSM) for many years, and have gradually gained recognition worldwide. The role of herbal medicines in the comprehensive treatment of DSM is being improved from adjuvant treatment of the autologous immune function in cancer patients, to the treatment of both the symptoms and disease, direct inhibition of tumor cell growth and proliferation, and induction of tumor cell autophagy and apoptosis. Their specific mechanisms in these treatments are also being explored. The paper reviews the current anti-tumor mechanisms of TCM, including single herbal medicines, Chinese herbal formulations, Chinese medicine preparations and TCM extract, and their application in the comprehensive treatment of digestive system tumors, providing a reference for clinical application of TCM.

show abstract

Transarterial chemoembolization combined with Huaier granule for the treatment of primary hepatic carcinoma

Cited by 32 publications

References 20 publications

The effects of a prior malignancy on the survival of patients with ovarian cancer: a population-based study

The effects of a prior malignancy on the survival of patients with ovarian cancer: a population-based study

The Chinese Medicine, Jiedu Recipe, Inhibits the Epithelial Mesenchymal Transition of Hepatocellular Carcinoma via the Regulation of Smad2/3 Dependent and Independent Pathways

Recent Advances in Herbal Medicines for Digestive System Malignancies

Contact Info

Product

Resources

About